程序性細胞死亡配體1（PD-L1），也稱為B7-H1或CD274，是一種B7家族蛋白，參與調節和減弱適應性免疫應答和外周T細胞耐受性。1、2、3、4它是一種290個氨基酸的I型跨膜蛋白，在人類中由CD274編碼，一個IgV樣結構域，一個IgC樣結構域、一個跨膜結構域和一個細胞質尾部。PD-L1在T和B細胞、樹突狀細胞、巨噬細胞和調節性T細胞（Tregs）以及多種非造血細胞中組成性表達，并被IFN-γ上調，抑制T細胞增殖、遷移和細胞因子產生。PD-L1也在多種腫瘤細胞中異常表達，腫瘤組織中PD-L1的表達與腎細胞癌患者的不良預后相關。含有PD-L1阻斷抗體的制劑已用于治療多種癌癥。Cayman的PD-L1/CD274兔單克隆抗體（APC）由與別藻藍蛋白（APC）綴合的PD-L1/CD274單克隆抗體組成，可用于流式細胞術。

Cayman Chemical艾美捷PD-L1/CD274兔單克隆抗體技術參數：

免疫原：重組小鼠PD-L1

配方：蛋白A親和純化單克隆抗體

宿主：兔子

同種型：IgG抗體

應用：FC、Cross Reactivity、(+) PD-L1

存儲：4攝氏度

穩定性：≥1年

Cayman Chemical艾美捷PD-L1/CD274兔單克隆抗體相關文獻：

1. Fabrizio, F.P., Trombetta, D., Rossi, A., et al. Gene code CD274/PD-L1: From molecular basis toward cancer immunotherapy. Ther. Adv. Med. Oncol. 10, (2018).

2. Riley, J.L. PD-1 signaling in primary T cells. Immunol. Rev. 229(1), 114-125 (2009).

3. del Rio, M.L., Buhler, L., Gibbons, C.E., et al. PD-1/PD-L1, PD-1/PD-L2, ａnd other co-inhibitory signaling pathways in transplantation. Transpl. Int. 21(11), 1015-1028 (2008).

4. Akinleye, A., ａnd Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol. Oncol. 12(1), 92 (2019).

5. Keir, M.E., Butte, M.J., Freeman, G.J., et al. PD-1 ａnd its ligands in tolerance ａnd immunity. Annu. Rev. Immunol. 26, 677-704 (2008).

6. Ji, M., Liu, Y., Li, Q., et al. PD-1/PD-L1 pathway in non-small-cell lung cancer ａnd its relation with EGFR mutation. J. Transl. Med. 13, 5 (2015).

7. Thompson, R.H., Dong, H., Lohse, C.M., et al. PD-1 is expressed by tumor-infiltrating immune cells ａnd is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13(6), 1757-1761 (2007).

8. Thompson, R.H., Kuntz, S.M., Leibovich, B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006).

Cayman Chemical涉及癌癥、腫瘤、氧化損傷、凋亡、氧化性損傷、代謝、內分泌學等多種研究域。艾美捷科技是Cayman Chemical的中國代理商，為科研工作者提供優質的產品與服務。

來源：https://www.amyjet.com/brand/cayman-china-distributor.shtml